Talibong, Danilyn C.
HRN: 23-62-29 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
11/10/2023
CO-AMOXICLAV 625MG (TAB)
11/10/2023
11/16/2023
PO
625
BId
Perineal Swelling;nsvd With Episio
Checking Final Appropriateness
Indication: Prophylaxis Type of Infection: Prophylaxis Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes